Cipher Pharmaceuticals’ Partner Moberg Pharma AB Reports Phase 3 Study Results for MOB-015Business PenDecember 11, 2024 December 11, 2024 Cipher Pharmaceuticals Inc. (TSX: CPH, OTCQX: CPHRF) has recently faced a setback as its partner, Moberg Pharma AB, announced that the Phase 3 clinical trial...
